Skip Navigation


NDT Advance Access originally published online on August 14, 2007
Nephrology Dialysis Transplantation 2007 22(11):3107-3109; doi:10.1093/ndt/gfm469
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
22/11/3107    most recent
gfm469v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Li, J.
Right arrow Articles by Unger, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, J.
Right arrow Articles by Unger, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org


Inflammation in the genesis of hypertension and its complications—the role of angiotensin II

Jun Li1, Yvonne Doerffel2, Berthold Hocher1 and Thomas Unger1

1Center for Cardiovascular Research (CCR)/Institute of Pharmacology, and 2Outpatient Clinic, Charité – Universitätsmedizin Berlin, Germany

Correspondence and offprint requests to: Prof. Dr. med. Thomas Unger, Center for Cardiovascular Research (CCR)/Institute of Pharmacology, Charité – Universitätsmedizin Berlin, Hessische Street 3-4, 10115 Berlin, Germany. Email: thomas.unger@charite.de

Keywords: hypertension; inflammation; angiotensin II

The first 10% of the full text of this article appears below.

Hypertension remains a major clinical syndrome characterized by small artery disease and subsequent accentuated development of atherosclerosis [1]. The affected arteries usually have diminished wall compliance and elevated stiffness resulting from arterial remodelling and atherosclerosis. With the progression of hypertension, the risk of cardiovascular complications such as myocardial infarction and stroke increases [2]. Recently, an emerging concept contends that inflammation plays a predominant role in the progression of hypertension and is also involved in the triggering of hypertension-associated cardiovascular complications.



   Inflammation and hypertension
 
Recent studies have indicated a close relationship between hypertension and inflammation, showing that tissue expression and plasma concentration of inflammatory mediators are increased in patients with essential hypertension and in experimental models of hypertension. These inflammatory mediators include C . . . [Full Text of this Article]



   Proinflammatory angiotensin II
 


   Anti-inflammatory effects by inhibition of the RAS
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?